Advertisement
RayBiotech
RayBiotech

The Scientist

» pharmaceuticals and developmental biology

Most Recent

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: Dino Snouts from Chicken Beaks

Dino Snouts from Chicken Beaks

By | May 13, 2015

Researchers tweak gene expression in chicken embryos that may have been crucial to the evolutionary transition from dinosaur noses to bird bills.

0 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

image: Viral Protector

Viral Protector

By | April 21, 2015

A retrovirus embedded in the human genome may help protect embryos from other viruses, and influence fetal development.

1 Comment

image: Contributors

Contributors

By | April 1, 2015

Meet some of the people featured in the April 2015 issue of The Scientist.

0 Comments

image: From Many, One

From Many, One

By | April 1, 2015

Diverse mammals, including humans, have been found to carry distinct genomes in their cells. What does such genetic chimerism mean for health and disease?

4 Comments

image: Short, Strong Signals

Short, Strong Signals

By | March 25, 2015

Methylation increases both the activity and instability of the signaling protein Notch.

0 Comments

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Shire Makes $5.2 Billion Buy

Shire Makes $5.2 Billion Buy

By | January 13, 2015

The Irish drugmaker moves on from its terminated sale to AbbVie to purchase New Jersey-based NPS Pharmaceuticals.

0 Comments

image: Spinoff Company to Develop Rare Disease Drugs

Spinoff Company to Develop Rare Disease Drugs

By | January 7, 2015

Maryland-based Vtesse will work with the US National Institutes of Health to advance treatments for Niemann-Pick Type C disease and other lysosomal storage disorders.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
LI-COR
LI-COR

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement